左炔诺孕酮宫内系统预防肥胖女性子宫内膜癌的成本效果研究
该研究采用马尔可夫决策分析模型,比较5种策略在BMI≥30女性中预防子宫内膜癌的成本效果。结果显示,LNG-IUS在不同起始年龄下具有成本效果,但结果对LNG-IUS的风险降低估计和肥胖对发病率及死亡率的影响敏感。
要点
- LNG-IUS是肥胖女性预防子宫内膜癌的成本效果方法。
- 成本效果阈值假设为每挽救生命年低于66,400加元(50,000美元)。
- 策略2在57岁插入LNG-IUS时具成本效果,策略5在45岁时具成本效果。
核心结论
- LNG-IUS是肥胖女性预防子宫内膜癌的成本效果方法。
研究设计与样本
- 马尔可夫决策分析模型,比较5种策略在BMI≥30女性中的成本效果。
- 策略包括:常规护理、LNG-IUS使用5年、7年、5年更换一次共10年、7年更换一次共14年。
- 假设肥胖与子宫内膜癌发病率3倍相对风险和疾病特异性死亡率2.65倍相关。
- 假设LNG-IUS在插入期间 confer 50%的癌症发病率降低。
- 结局为增量成本效果比,以2019年加拿大元每挽救生命年计算。
主要发现
- LNG-IUS策略在干预成本低于每挽救生命年66,400加元(50,000美元)时被认为具成本效果。
- 与常规护理相比,策略2在57岁插入LNG-IUS时具成本效果。
- 策略3在52岁、策略4在51岁、策略5在45岁时具成本效果。
- 结果对成本变化稳定,但对LNG-IUS的风险降低估计和肥胖对子宫内膜癌发病率及死亡率的影响敏感。
关键数值与推荐
- 成本效果阈值:每挽救生命年低于66,400加元(50,000美元)。
- 肥胖相关子宫内膜癌发病率相对风险:3倍。
- 肥胖相关疾病特异性死亡率:2.65倍。
- LNG-IUS assumed 50% reduction in cancer incidence over insertion period。
临床怎么用
- 对于肥胖女性,可考虑使用LNG-IUS预防子宫内膜癌,尤其在特定年龄起始时具成本效果。
局限性
- 结果对LNG-IUS的风险降低估计和肥胖对子宫内膜癌发病率及死亡率的影响敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the cost-effectiveness of the levonorgestrel intrauterine system (LNG-IUS) as an endometrial cancer prevention strategy in women with obesity. METHODS: A Markov decision-analytic model was used to compare 5 strategies in women with a body mass index of 30 or greater: 1) Usual care 2) LNG-IUS for 5 years 3) LNG-IUS for 7 years 4) LNG-IUS for 5 years, replaced once for a total of 10 years 5) LNG-IUS for 7 years, replaced once for a total of 14 years. Obesity was presumed to be associated with a 3-fold relative risk of endometrial cancer incidence and a 2.65-fold disease-specific mortality. The LNG-IUS was assumed to confer a 50% reduction in cancer incidence over the period of the LNG-IUS insertion. Outcomes were incremental cost-effectiveness ratios, calculated in 2019 Canadian dollars (CAD) per year of life saved. One-way and two-way sensitivity analyses were performed. RESULTS: The LNG-IUS strategy was considered cost-effective if the cost of the intervention is less than $66,400 CAD ($50,000 US dollars) per year of life saved. The strategy becomes cost-effective if the LNG-IUS is inserted at age 57 (strategy #2), at age 52 for strategy #3, at age 51 for strategy #4 and at age 45 for strategy #5, when compared to usual care. The results are stable to variations in cost but sensitive to the estimated risk reduction of the LNG-IUS and the impact of obesity on endometrial cancer incidence and disease-specific mortality. CONCLUSION: The LNG-IUS is a cost-effective method of endometrial cancer prevention in women with obesity.
引用
- Bernard L, Kwon JS, Simpson AN, et al. The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study. Gynecol Oncol. 2021. PMID: 33648747. doi:10.1016/j.ygyno.2021.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。